Exogenous FLCN mRNA Restores Function in BHD Syndrome Mutants

Study Background and Research Question

Birt-Hogg-Dubé (BHD) syndrome is a rare autosomal dominant disorder characterized by lung cysts, spontaneous pneumothorax, cutaneous fibrofolliculomas, and renal tumors. It is caused by germline mutations in the folliculin (FLCN) gene, a tumor suppressor located on chromosome 17p11.2. Despite its distinct clinical phenotype, BHD remains underdiagnosed, particularly in non-European populations, and lacks curative therapies—current management is largely supportive. The prevalence of BHD is low, estimated at approximately two cases per million in the general population according to the reference study. The study by Bai et al. addresses two central questions: What is the pathogenicity of rare FLCN variants identified in Chinese BHD families, and can mRNA-based protein replacement restore FLCN function in vitro?

Key Innovation from the Reference Study

The pivotal advance of this research lies in two areas. First, it expands the known mutational spectrum of FLCN in BHD by identifying a novel nonsense variant (p.Q44*) and providing functional evidence for the pathogenicity of a previously uncertain missense variant (p.W376R). Second, and most notably, the study provides robust in vitro evidence that exogenous FLCN mRNA delivery can rescue protein expression and reverse mTORC1 dysregulation caused by loss-of-function mutations. This establishes a foundational proof-of-concept for mRNA-based therapeutic strategies targeting monogenic diseases with loss-of-function alleles, such as BHD syndrome (Bai et al., 2026).

Methods and Experimental Design Insights

The study employed a family-based prospective cohort design, enrolling two Chinese families with suspected BHD syndrome. The workflow comprised:

• Whole-exome sequencing (WES) to identify candidate FLCN mutations in probands, followed by Sanger sequencing to confirm familial co-segregation.
• Bioinformatic and quantitative PCR analyses to assess the predicted and observed impacts of the p.W376R missense mutation on protein function.
• Functional assays in HEK293T cells, involving transfection with empty vector, wild-type or mutant FLCN plasmids (p.W376R and p.Q44*), and subsequent cotransfection with synthetic FLCN mRNA.
• Assessment of FLCN protein expression and mTORC1 pathway activity by immunoblotting and related molecular assays.

This integrative approach enabled both molecular genetic diagnosis and mechanistic validation of mRNA-mediated functional rescue.

Core Findings and Why They Matter

Key discoveries from the reference study include:

• Rare FLCN mutations identified: In both families, affected members harbored either the p.W376R missense variant (previously classified as a Variant of Uncertain Significance) or a novel nonsense mutation (p.Q44*). Both variants were associated with predominant respiratory symptoms, with an absence of typical skin lesions or kidney tumors, highlighting clinical heterogeneity in BHD presentations.
• Genotype–phenotype co-segregation and functional validation: The p.W376R variant was confirmed to co-segregate with disease in the family and, together with p.Q44*, resulted in markedly reduced FLCN protein expression and mTORC1 pathway hyperactivation in vitro.
• mRNA-based rescue: Exogenous delivery of synthetic FLCN mRNA into mutant-expressing HEK293T cells restored FLCN protein levels and reversed mTORC1 dysregulation, demonstrating that mRNA supplementation can functionally compensate for loss-of-function mutations.

These findings are significant because they not only expand the catalog of pathogenic FLCN mutations but also establish a mechanistic rationale for pursuing mRNA-based protein replacement as a therapeutic strategy in BHD and potentially other monogenic disorders with similar pathogenic profiles.

Comparison with Existing Internal Articles

This reference study's results are consistent with and extend the observations reported in several internal resources. For example, the internal article "Novel FLCN Mutations and mRNA Rescue in Birt-Hogg-Dubé Syndrome" also highlights the identification of new FLCN mutations and provides functional evidence for mRNA-mediated rescue of protein expression and mTORC1 signaling. Moreover, another internal summary discusses the broader significance of these findings as a proof-of-concept for mRNA therapy in loss-of-function genetic diseases.

From a methodological perspective, internal articles—such as "Advancing mRNA Rescue: Mechanisms and Strategy for FLCN in BHD"—emphasize the importance of robust in vitro RNA synthesis platforms for generating therapeutic mRNA. These articles analyze how high-yield, precise synthesis (e.g., using a T7 RNA polymerase in vitro transcription kit) underpins translational mRNA rescue workflows, reinforcing the practical relevance of the reference study's approach.

Limitations and Transferability

While the study provides compelling evidence for the feasibility of mRNA-based protein replacement in vitro, several limitations remain. The experiments were limited to cell-based models (HEK293T cells), and the efficacy, safety, and delivery efficiency of FLCN mRNA in vivo—particularly in target tissues such as the lung, kidney, or skin—were not addressed. The small sample size (two families) also restricts generalizability regarding the clinical spectrum and mutation prevalence in broader populations. Furthermore, the long-term stability and immunogenicity of exogenous mRNA in clinical settings are unresolved.

Despite these caveats, the transferable lesson is clear: mRNA intervention can directly address loss-of-function mutations at the protein expression level, providing a platform for rapid therapeutic prototyping in rare genetic disorders. This approach is relevant not only for BHD but also for research into RNA vaccine synthesis, antisense RNA production, and ribozyme biochemistry, where precise and high-yield RNA synthesis technologies are required.

Protocol Parameters

• Template design: Use linearized plasmid DNA encoding the full-length wild-type or mutant FLCN open reading frame. Ensure template integrity for efficient transcription.
• In vitro transcription: Employ a T7 RNA polymerase in vitro transcription kit for high-yield production of capped, modified, or dye-labeled FLCN mRNA. Follow recommended reaction conditions to maximize RNA integrity and yield.
• RNA purification: Purify the synthesized RNA using silica membrane–based spin columns or magnetic beads, such as the RNA Clean and Concentrator Kit or Oligo (dT)25 Beads if poly(A) tailing is required.
• Transfection: Optimize mRNA transfection protocols for your cell line of interest. Lipid-based transfection reagents are commonly used for HEK293T cells.
• Functional assay timing: Assess protein expression and downstream signaling (e.g., mTORC1 activity) 24–48 hours post-transfection.

Research Support Resources

For researchers seeking to replicate or extend these mRNA-based intervention workflows, access to reliable in vitro RNA synthesis platforms is critical. The HyperScribe™ T7 High Yield RNA Synthesis Kit Plus (SKU K1401) provides a robust solution for high-yield, customizable RNA synthesis—including capped, dye-labeled, or biotinylated transcripts—supporting applications in RNA interference experiments, RNA vaccine synthesis, and therapeutic mRNA research. The kit's protocol flexibility and troubleshooting guidance can facilitate efficient translation of experimental strategies, as demonstrated in recent BHD studies. For further details on optimized mRNA rescue workflows and translational applications, refer to the internal review, "HyperScribe T7 High Yield RNA Synthesis Kit Plus: Translational mRNA Rescue Workflows".